GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Jupiter Neurosciences Inc
Shares of Jupiter Neurosciences, a company developing drugs to treat neurodegenerative diseases, are a highly speculative bet on its scientific platform. Their price is driven by news from preclinical and early clinical trials.
Share prices of companies in the market segment - Neuro
Jupiter Neurosciences is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's. We've categorized it under "Neurology," and the chart below shows how investors assess the risks and prospects in this complex area of medicine.
Broad Market Index - GURU.Markets
Jupiter Neurosciences is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's. It is a component of the GURU.Markets index. The chart below represents the market. See how this stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
JUNS - Daily change in the company's share price Jupiter Neurosciences Inc
Jupiter Neurosciences Inc.'s daily share price fluctuations reflect the high volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its drugs for treating neurodegenerative diseases.
Daily change in the price of a set of shares in a market segment - Neuro
Jupiter Neurosciences, Inc. is a biotech company. This chart shows the extreme volatility of the sector. Comparison with JUNS, which focuses on neurodegenerative diseases, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Jupiter Neurosciences is a biotech company developing drugs to treat neurodegenerative diseases. Its shares are driven by news of clinical trials. This high volatility, driven by innovation, is a significant contributor to the overall "noise" and dynamics of the stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Jupiter Neurosciences Inc
Jupiter Neurosciences Inc.'s year-over-year performance is a story of developing a new approach to treating neurodegenerative diseases. Its 12-month market cap is entirely dependent on progress in clinical trials of its lead drug, which targets oxidative stress in conditions such as ALS and Alzheimer's disease.
Annual dynamics of market capitalization of the market segment - Neuro
As an early-stage biotech, Jupiter is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news of clinical trials. Its stock price will reflect investors' speculative belief in the potential of its unique neuroscience developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Jupiter Neurosciences is a very small and highly speculative biotech company. Its stock price has nothing to do with fundamentals or the economy, but is driven by news of trials and investor confidence in the potential of its developments, making it a high-risk bet.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Jupiter Neurosciences Inc
Jupiter Neurosciences is a biopharmaceutical company developing drugs for the treatment of neurodegenerative diseases. Its monthly performance is entirely dependent on progress in its clinical trials. News of its lead candidate's clinical trial results is the main driver.
Monthly dynamics of market capitalization of the market segment - Neuro
Drug development for neurological diseases is an area with a huge unmet need, but also high R&D risks. The dynamics of this biotech sector, shown in the chart, reflect this volatility. Companies like Jupiter Neurosciences are active in this field.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Jupiter Neurosciences Inc. is a clinical-stage biotech company focused on treating neurodegenerative diseases. Its stock is a classic venture bet. Its performance is entirely dependent on the success or failure of clinical trials and has no correlation to broader market movements.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Jupiter Neurosciences Inc
For Jupiter Neurosciences, an early-stage biopharmaceutical company, weekly performance is extremely volatile. Any news about the development of its Alzheimer's drug, even at the preclinical level, triggers sharp speculative movements.
Weekly dynamics of market capitalization of the market segment - Neuro
Jupiter Neurosciences and the entire neuroscience biotech sector are driven by overall investor sentiment and news of breakthroughs. The success or failure of one major study can impact the entire industry. The chart shows how the company fares against this volatile backdrop.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Jupiter Neurosciences and the entire neuroscience biotech sector are driven by overall investor sentiment and news of breakthroughs. The success or failure of one major study can impact the entire industry. The chart shows how the company fares against this volatile backdrop.
Market capitalization of the company, segment and market as a whole
JUNS - Market capitalization of the company Jupiter Neurosciences Inc
The Jupiter Neurosciences market capitalization chart represents the financial valuation of an early-stage biotech company developing treatments for neurodegenerative diseases. It reflects investor expectations for its lead drug candidate. Its speculative dynamics tell the story of how the market evaluates science in the absence of clinical data and revenue.
JUNS - Share of the company's market capitalization Jupiter Neurosciences Inc within the market segment - Neuro
Jupiter Neurosciences is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). Its sector share reflects the potential of its lead candidate, a resveratrol-based drug. The chart below illustrates the market's confidence in its scientific approach.
Market capitalization of the market segment - Neuro
Jupiter Neurosciences develops drugs to treat neurodegenerative diseases. The chart below shows the overall market capitalization of the entire sector. Its dynamics reflect hopes for breakthroughs in the treatment of diseases like Alzheimer's. Jupiter, like many others, is part of this complex scientific endeavor.
Market capitalization of all companies included in a broad market index - GURU.Markets
The neurological diseases visible in the chart require new approaches. Jupiter Neurosciences Inc. is developing a resveratrol-based drug for the treatment of Alzheimer's disease. Its small market capitalization reflects the very early stage of development and the extremely high risk associated with research in this area.
Book value capitalization of the company, segment and market as a whole
JUNS - Book value capitalization of the company Jupiter Neurosciences Inc
Jupiter Neurosciences' book value is capital invested in the treatment of neuroinflammation. Currently in the R&D stage, the company is using its financial assets to develop a unique resveratrol formula that can cross the blood-brain barrier to treat Alzheimer's disease and other conditions.
JUNS - Share of the company's book capitalization Jupiter Neurosciences Inc within the market segment - Neuro
Jupiter Neurosciences, a clinical-stage biopharmaceutical company, focuses on neurodegenerative diseases. Its stake in the sector is minimal. The company's value lies in its intellectual property and the potential of its lead drug.
Market segment balance sheet capitalization - Neuro
Jupiter Neurosciences Inc. is a clinical-stage biotech company, which accounts for its low capital intensity. Its value lies in developing drugs for the treatment of neurodegenerative diseases. Compared to the pharmaceutical sector, its "light" balance sheet is typical of companies focused on R&D.
Book value of all companies included in the broad market index - GURU.Markets
Jupiter Neurosciences' assets are not new molecules, but a unique formula that improves the delivery of resveratrol to the brain for the potential treatment of Alzheimer's disease. The company's balance sheet reflects the value of this development. The chart shows the capital invested in this new approach to treating neurodegenerative diseases.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Jupiter Neurosciences Inc
Jupiter Neurosciences is a biopharmaceutical company focused on treating neurodegenerative diseases. Its market value is determined by its scientific approach and the potential of its lead drug. This is a bet on success in one of the most challenging areas of medicine.
Market to book capitalization ratio in a market segment - Neuro
Jupiter Neurosciences develops drugs to treat neurodegenerative diseases. Like many early-stage biotechs, its market valuation is a bet on the success of future clinical trials. This chart shows the vast gap between that hope and its stock price.
Market to book capitalization ratio for the market as a whole
Jupiter Neurosciences is a biopharmaceutical company developing drugs to treat neurological diseases. Its market capitalization is based on the potential of its scientific research. This chart demonstrates how much a biotech company's valuation can exceed its book value thanks to the strength of its intellectual property.
Debts of the company, segment and market as a whole
JUNS - Company debts Jupiter Neurosciences Inc
Jupiter Neurosciences develops drugs to treat neurodegenerative diseases. For a small, early-stage biotech company, debt financing can be risky, but it can serve as a bridge between equity rounds to maintain the pace of research.
Market segment debts - Neuro
Jupiter Neurosciences is a biopharmaceutical company developing drugs to treat neurodegenerative diseases. Funding at the R&D stage is key. This chart shows the company's chosen funding route for its research: a traditional equity offering or other forms of capital, which is important for assessing its progress.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Jupiter Neurosciences Inc
Jupiter Neurosciences, a biopharmaceutical company focused on neurodegenerative diseases such as Alzheimer's, shows its leverage. Drug development in this area is one of the most complex and expensive challenges in medicine, so high debt poses enormous risks.
Market segment debt to market segment book capitalization - Neuro
Jupiter Neurosciences develops drugs to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). This chart compares the debt it raised to fund clinical trials to the total market capitalization of the entire neuroscience sector. It illustrates the financial implications of fighting some of the most devastating diseases.
Debt to book value of all companies in the market
Jupiter Neurosciences develops drugs to treat neurodegenerative diseases. This is a long and risky path, requiring significant capital. The chart shows how the company finances its research. Its debt load, compared to other clinical-stage biotech companies, is an important indicator of its financial health and strategy.
P/E of the company, segment and market as a whole
P/E - Jupiter Neurosciences Inc
For Jupiter Neurosciences, a company developing drugs to treat neurodegenerative diseases, this chart is a pure bet on science. Investors' estimates of its potential profits are based on hopes for breakthroughs in the treatment of diseases like Alzheimer's. The dynamics reflect news about the progress of clinical trials.
P/E of the market segment - Neuro
This chart reflects the average valuation for the speculative biotech sector—a benchmark for Jupiter Neurosciences. For investors, it's a benchmark indicating the overall level of optimism in the field of neurodegenerative disease treatments. This provides a useful backdrop for assessing expectations for the company's developments.
P/E of the market as a whole
Jupiter Neurosciences develops drugs to treat neurodegenerative diseases such as Alzheimer's. The company operates in one of the most complex and risky areas of pharmaceuticals. This chart shows the market's risk appetite. It provides insight into how the market views the company's scientific approach and its chances of succeeding where many industry giants have failed.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Jupiter Neurosciences Inc
Jupiter Neurosciences is a biopharmaceutical company developing a drug for the treatment of mucopolysaccharidosis type 1 and potentially other neurodegenerative diseases. This chart reflects analyst expectations for its clinical development. It demonstrates the market's confidence in the company's scientific potential and its ability to bring a new treatment to market.
%20P%2FE%20Jupiter%20Neurosciences%20Inc&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Jupiter-Neurosciences-Inc&v=1772621413590 "Chart of the company's future (projected) P/E Jupiter Neurosciences Inc")
Future (projected) P/E of the market segment - Neuro
Jupiter Neurosciences develops drugs to treat neurodegenerative diseases such as Alzheimer's using a novel approach targeting oxidative stress. This chart compares its future profitability expectations with the biotech sector, demonstrating the market's confidence in its scientific hypothesis and the potential of its lead candidate in clinical trials.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772621413617 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Jupiter Neurosciences develops drugs to treat neurodegenerative diseases. This chart shows the overall risk appetite. JUNS's success depends solely on clinical trial results. A positive market environment helps attract capital, but cannot replace strong scientific data.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772621413636 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Jupiter Neurosciences Inc
Jupiter Neurosciences is a clinical-stage biopharmaceutical company developing drugs for the treatment of neurodegenerative diseases such as Alzheimer's. This chart illustrates the financial impact of research. Current results reflect investments in development and clinical trials.
Profit of companies in the market segment - Neuro
Jupiter Neurosciences is a biopharmaceutical company developing a drug to treat mucopolysaccharidosis type 1, a rare genetic disorder, and is also exploring its potential for other neurological disorders. This chart illustrates the total revenue in the neuroscience sector, demonstrating how companies are working to develop drugs for orphan diseases.
Overall market profit
Jupiter Neurosciences is a biopharmaceutical company developing drugs to treat neurodegenerative diseases. Its success depends on the results of clinical trials. The need for treatments for conditions like Alzheimer's disease is enormous and independent of economic cycles. However, access to capital is essential for funding development.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Jupiter Neurosciences Inc
Jupiter Neurosciences is a pharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's. This is one of the most complex areas in medicine. Its profit projections reflect extremely high risks, but also the enormous potential for success in the event of a breakthrough.
%20profit%20of%20the%20company%20Jupiter%20Neurosciences%20Inc&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Jupiter-Neurosciences-Inc&v=1772621413707 "Graph of future (projected) profit of the company Jupiter Neurosciences Inc")
Future (predicted) profit of companies in the market segment - Neuro
Jupiter Neurosciences develops drugs to treat neurodegenerative diseases such as Alzheimer's using a novel approach to active substance delivery. This chart shows forecasts for the biotech sector. The company's future profitability depends entirely on the success of its lead candidate in clinical trials and its potential to transform the treatment of these devastating diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772621413754 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Jupiter Neurosciences develops drugs to treat neurodegenerative diseases. Funding for such long-term and risky projects is highly dependent on the overall stock market. This graph, showing profit expectations, is an indicator of the investment climate and investor risk appetite, which is critical for the biotech sector.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772621413785 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Jupiter Neurosciences Inc
Jupiter Neurosciences develops drugs to treat neurodegenerative diseases such as Alzheimer's. Being in the early stages, the company has minimal revenue. This chart demonstrates that its valuation is based solely on investor expectations for the clinical success of its developments.
P/S market segment - Neuro
Jupiter Neurosciences develops drugs to treat neurodegenerative diseases such as amyotrophic lateral sclerosis and Alzheimer's disease using a novel approach to delivering active substances to the brain. This chart reflects the average biotech valuation, helping to understand how highly the market values the potential of Jupiter Neurosciences' scientific platform.
P/S of the market as a whole
Jupiter Neurosciences is developing resveratrol-based drugs for the treatment of neurodegenerative diseases such as Alzheimer's. This is a high-risk area of research. This market valuation indicator highlights that investors are not evaluating current sales, but rather the hope for a scientific breakthrough in one of the most complex areas of medicine.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Jupiter Neurosciences Inc
Jupiter Neurosciences develops drugs to treat neurodegenerative diseases such as Alzheimer's. This chart reflects investor expectations for the future success of its clinical programs. The valuation is based on the potential revenue from its drugs, which target large markets with unmet medical needs.
%20P%2FS%20Jupiter%20Neurosciences%20Inc&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Jupiter-Neurosciences-Inc&v=1772621413885 "The graph of the company's future (projected) P/S Jupiter Neurosciences Inc")
Future (projected) P/S of the market segment - Neuro
Jupiter Neurosciences develops drugs to treat neurodegenerative diseases such as amyotrophic lateral sclerosis. This chart compares the company's future revenue expectations with its industry sector. It reflects investor confidence in the scientific potential of its developments and future commercial success.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772621413897 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Jupiter Neurosciences develops drugs to treat neurodegenerative diseases such as Alzheimer's using its unique drug delivery platform. This schedule reflects confidence in future growth, as Jupiter tackles one of medicine's most challenging problems. The success of its technology could bring hope to millions of patients.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772621413911 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Jupiter Neurosciences Inc
Jupiter Neurosciences is a clinical-stage biopharmaceutical company developing drugs for the treatment of neurodegenerative diseases. The company currently has no commercial sales revenue. Any revenue reflected in this chart likely comes from grants or early partnerships.
Sales of companies in the market segment - Neuro
Jupiter Neurosciences develops drugs to treat neurodegenerative diseases such as Alzheimer's using a novel approach to delivering active agents to the brain. This graph reflects the tremendous need and investment in drug discovery for CNS diseases, where innovations like Jupiter's offer new hope.
Overall market sales
Jupiter Neurosciences Inc. is a clinical-stage biopharmaceutical company focused on treating neurodegenerative diseases. Its operations require significant capital investment. The growth in overall economic activity, reflected in this chart, creates a more favorable environment for raising capital, allowing companies like Jupiter to fund their long-term scientific programs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Jupiter Neurosciences Inc
Jupiter Neurosciences Inc. is a biopharmaceutical company developing a resveratrol-based drug for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). This chart reflects analyst expectations for the success of clinical trials and potential approval of its candidate.
%20sales%20of%20the%20company%20Jupiter%20Neurosciences%20Inc&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Jupiter-Neurosciences-Inc&v=1772621414196 "Schedule of future (projected) sales of the company Jupiter Neurosciences Inc")
Future (projected) sales of companies in the market segment - Neuro
Jupiter Neurosciences is developing drugs to treat neurodegenerative diseases such as amyotrophic lateral sclerosis using a new form of resveratrol. This chart shows forecasts for the neuroscience sector. It provides context for assessing how innovative approaches to delivering known molecules can open up new therapeutic opportunities.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772621414226 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Jupiter Neurosciences, which develops drugs to treat neurodegenerative diseases, sees this chart as an indicator of the investment climate. The strong economic outlook reflected here encourages capital inflows into biotech, which is necessary to fund lengthy and expensive clinical trials.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772621414236 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Jupiter Neurosciences Inc
Jupiter Neurosciences is an early-stage biopharmaceutical company developing treatments for neurodegenerative diseases. This chart reflects its current status: it is in the intensive research and development phase, requiring significant investment. It shows how capital is being directed toward science in the hopes of a future breakthrough, rather than current profits.
Market segment marginality - Neuro
Jupiter Neurosciences develops drugs to treat neurodegenerative diseases such as Alzheimer's. In this highly complex and risky field of pharmaceuticals, operational efficiency lies in conducting research as cost-effectively as possible. The chart shows how the company manages its resources in the race for a breakthrough drug.
Market marginality as a whole
Jupiter Neurosciences develops drugs to treat neurodegenerative diseases. This chart shows current profitability, and Jupiter Neurosciences invests in solving some of the most complex medical problems. Their financial history is a journey of research and development in anticipation of a clinical breakthrough.
Employees in the company, segment and market as a whole
Number of employees in the company Jupiter Neurosciences Inc
Jupiter Neurosciences is a biopharmaceutical company developing drugs to treat neurodegenerative diseases. This chart shows its compact team. A small staff allows the company to effectively manage its resources, focusing on advancing its lead candidate through clinical trials.
Share of the company's employees Jupiter Neurosciences Inc within the market segment - Neuro
Jupiter Neurosciences is developing new treatments for neurodegenerative diseases like Alzheimer's using its unique platform. This chart shows the percentage of all scientists working in this complex field that Jupiter attracts, a measure of its scientific potential and focus on one of medicine's biggest challenges.
Number of employees in the market segment - Neuro
Jupiter Neurosciences is a biopharmaceutical company developing drugs to treat neurodegenerative diseases. Its staff is small and focused on research. This graph shows that the company is in the early stages. Staffing trends will reflect progress in preclinical and early clinical trials.
Number of employees in the market as a whole
Jupiter Neurosciences develops drugs to treat neurodegenerative diseases. Biopharmaceutical companies thrive on the rhythm of scientific discovery. This chart shows the overall picture, but for JNS, a breakthrough in Alzheimer's research will mean explosive growth, regardless of the state of the economy.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Jupiter Neurosciences Inc (JUNS)
Jupiter Neurosciences is an R&D company focused on neurological diseases. Its market capitalization reflects investors' hopes for the success of its research. The very high value on this chart is typical for biotech, where a small team of scientists can create a product worth billions of dollars.
%20of%20the%20company%20Jupiter%20Neurosciences%20Inc%20(JUNS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Jupiter-Neurosciences-Inc-JUNS&v=1772621414729 "Chart of market capitalization per employee (in thousands of dollars) of the company Jupiter Neurosciences Inc (JUNS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Jupiter Neurosciences Inc. develops drugs to treat neurodegenerative diseases. In this complex area of medicine, market valuation reflects the hopes for a scientific breakthrough. This metric demonstrates the value investors attribute to the intellectual potential of the team working on next-generation drugs.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772621414789 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Jupiter Neurosciences develops drugs to treat neurodegenerative diseases such as Alzheimer's. It's an early-stage biotech. The chart shows a high valuation per employee, as investors see enormous, albeit risky, potential in creating a cure for one of humanity's most complex diseases.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772621414872 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Jupiter Neurosciences Inc (JUNS)
Jupiter Neurosciences (JUNS) is a biopharmaceutical company developing drugs to treat neurodegenerative diseases (such as ALS) using its unique approach to drug delivery. It's an R&D company. This chart shows the R&D capital burn per scientist.
%20Chart%20Jupiter%20Neurosciences%20Inc%20(JUNS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Jupiter-Neurosciences-Inc-JUNS&v=1772621414940 "Company Profit Per Employee (in thousands of dollars) Chart Jupiter Neurosciences Inc (JUNS)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Jupiter Neurosciences (JUNS) is a biopharmaceutical company developing drugs for the treatment of neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). Being in the clinical stage, the company incurs high R&D expenses. This chart does not show operating profit, but rather the efficiency with which the research team uses capital to advance its research.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772621414975 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Jupiter Neurosciences is a biopharmaceutical company focused on treating neurodegenerative diseases (such as Alzheimer's). The company is in the R&D stage. This graph shows significant losses per employee. This reflects the high cost of research in one of the most complex areas of medicine, where the staff consists of highly paid specialists.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772621415026 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Jupiter Neurosciences Inc (JUNS)
Jupiter Neurosciences is a biopharmaceutical company developing drugs to treat neurodegenerative diseases. During the research phase, this graph is an indicator of future potential, not current sales. Any revenue per employee will likely come from strategic partnerships or grants.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Jupiter-Neurosciences-Inc-JUNS&v=1772621415059 "Sales chart per company employee Jupiter Neurosciences Inc (JUNS)")
Sales per employee in the market segment - Neuro
Jupiter Neurosciences is a biopharmaceutical company developing drugs (based on resveratrol) for the treatment of neurodegenerative diseases such as ALS. This chart shows the average revenue per employee in the sector. It serves as a benchmark, demonstrating the level of productivity required for commercial success in this complex field of neuroscience.
Sales per employee for the market as a whole
Jupiter Neurosciences Inc (JUNS) is a biopharmaceutical company developing drugs for the treatment of neurodegenerative diseases (such as ALS) using its unique platform (resveratrol). It is an R&D company. This chart shows the current (zero) commercial return per scientist.
Short shares by company, segment and market as a whole
Shares shorted by company Jupiter Neurosciences Inc (JUNS)
Jupiter Neurosciences (JUNS) is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's. It's a biotech "graveyard." The chart shows the number of investors betting that the company, like hundreds of others, will fail in clinical trials in this highly complex area of medicine.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Jupiter-Neurosciences-Inc-JUNS&v=1772621415197 "Short Shares Chart for the Company Jupiter Neurosciences Inc (JUNS)")
Shares shorted by market segment - Neuro
Jupiter Neurosciences is trying to improve drug delivery to the brain, specifically for the treatment of ALS. This chart demonstrates the skepticism surrounding this entire niche. Its growth suggests that investors are betting heavily against neuroscience development, which is known for its extremely high failure rate in clinical trials.
Shares shorted by the overall market
Jupiter Neurosciences is searching for cures for neurodegenerative diseases like Alzheimer's. It's the "holy grail" of biotech, but also a "graveyard" of clinical trials. This chart reflects the general fear. When the market is pessimistic, it doesn't believe in miracles. The risk of failure in Alzheimer's research is enormous, and investors are choosing to play it safe by selling JUNS shares.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Jupiter Neurosciences Inc (JUNS)
Jupiter Neurosciences is working on new treatments for neurodegenerative diseases like Alzheimer's, one of the most complex areas in biotech. This oscillator measures investor "fever": any hint of success in trials can trigger "overheating" (above 70), while failure can lead to deep "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Jupiter-Neurosciences-Inc-JUNS&v=1772621415311 "RSI 14 indicator chart for the company's stock Jupiter Neurosciences Inc (JUNS)")
RSI 14 Market Segment - Neuro
Jupiter Neurosciences (JUNS) is a "biotech" company, a "brain hunter." They are developing an improved (resveratrol) formula for the treatment of neurodegenerative diseases (Alzheimer's) and other diseases (e.g., MIPS). The "Neuro" (biotech) sector thrives on news. RSI\_14\_Seg shows the "temperature" of the entire segment. It helps us understand: is JUNS's growth due to their R&D, or is the entire biotech sector "overheated"?
RSI 14 for the overall market
Jupiter Neurosciences (JUNS) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast JUNS (Jupiter Neurosciences Inc)
Jupiter Neurosciences is a biotech company developing drugs to treat neurodegenerative diseases such as Alzheimer's. This chart shows the average 12-month target price of analysts. It reflects their collective assessment of the likelihood of clinical trial success and regulatory approval for their candidates.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-JUNS-Jupiter-Neurosciences-Inc&v=1772621415423 "A chart showing analyst consensus forecasts for the expected stock price. JUNS (Jupiter Neurosciences Inc)")
The difference between the consensus estimate and the actual stock price JUNS (Jupiter Neurosciences Inc)
Jupiter Neurosciences is a biotech company focused on developing drugs to treat neurodegenerative diseases such as Alzheimer's. This chart measures the gap between the current share price and the consensus target price. It shows the potential experts see in their highly risky, yet potentially breakthrough, R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-JUNS-Jupiter-Neurosciences-Inc&v=1772621415444 "A chart showing the difference between the consensus forecast and the actual stock price. JUNS (Jupiter Neurosciences Inc)")
Analyst consensus forecast for stock prices by market segment - Neuro
Jupiter Neurosciences is one of many biotech companies attempting to crack the Alzheimer's code by targeting neuroinflammation. It's the riskiest, yet most coveted, target in pharma. This chart shows analysts' overall expectations across the neuroscience sector, reflecting whether experts believe this long-awaited breakthrough in dementia treatment is possible.
Analysts' consensus forecast for the overall market share price
Jupiter Neurosciences is a biotech company focused on one of the most challenging areas: treating neurodegenerative diseases like Alzheimer's. This is a high-risk, long-term development area. This chart reflects the overall risk appetite in the market. For Jupiter, whose value is based on future hopes, the overall optimism of analysts is critical to funding multi-year trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Jupiter Neurosciences Inc
Jupiter Neurosciences is a clinical-stage biotech focused on the complex field of neuroscience, specifically Alzheimer's disease. Their key strategy is not a new molecule, but a new delivery system (JOTROL), designed to more effectively deliver existing treatments to the brain. This chart is a pure R&D indicator. Its dynamics reflect market speculation on their clinical data.
AKIMA Market Segment Index - Neuro
Jupiter Neurosciences (JUNS) is a biopharmaceutical company focused on treating neurodegenerative diseases such as Alzheimer's with its resveratrol-based drug, JOTROL. The chart shows the average index for the segment, allowing investors to weigh Jupiter Neurosciences' high risk and potential against the overall backdrop of the neurosciences sector.
The AKIM Index for the overall market
Jupiter Neurosciences is a pharmaceutical company developing resveratrol (JOTROL) for the treatment of rare diseases and aging. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative nutraceutical/pharma story compares to overall economic trends.
